The United States Patent and Trademark Office (USPTO) has recently issued to Immtech Pharmaceuticals, Inc. (Amex: IMM) a patent related to the manufacturing of Immtech's drug candidate compounds.
The patent, entitled "Process for the synthesis of bis-aryl diamidoxime compounds," claims a method for making drug candidate compounds, such as Immtech's pafuramidine maleate (DB289). This patent includes names of scientists from both the University of North Carolina at Chapel Hill and Georgia State University as inventors.
Read more at Immtech Pharma Inc. (a pdf file)."With the issuance of this patent, Immtech now has worldwide, exclusive rights to over 150 patents including claims to compositions, methods of use, and methods of manufacturing compounds in Immtech's large library.
This patent will further augment our patent estate and commercialization efforts. We are proud of the scientific accomplishments of our partner scientists and excited about Immtech's targeted markets."
Comment Preview